 Positron emission tomography computer tomography PETCT is a nuclear medicine diagnostic imaging procedure based on the measurement of positron emission from radiolabeled tracer molecules in vivo. A radiotracer in use today is 68Ga-HBED-CC-PSMA DKFZ-11 - hereinafter abbreviated 68Ga-PSMA - which is a radiolabeled urea-based ligand for prostate specific membrane antigen PSMA PETCT. Imaging with 68Ga-PSMA PET is used to characterize and localize prostate cancer in humans in vivo. There is extensive data in the literature showing the value of 68Ga-PSMA PETCT imaging in accurately staging and restaging prostate cancer. The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PETCT and to establish our ability to reproduce results from the literature using 68Ga-PSMA PETCT as a diagnostic and decision making tool in the management prostate cancer patients. During the study eligible prostate cancer patients will undergo one 68Ga-PSMA PETCT. The primary endpoints of the study are the incidence of adverse events AE in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PETCT vs CT on a per-patient and per-lesion basis. 